Primary non-Hodgkin's lymphoma of the uterus, cervix and parametrium treated by combined immunochemotherapy

Journal of Obstetrics and Gynaecology Research

Volumn 34, Issue SUPPL.1, 2008, Pages 749-753

  Su, Chi Feng ^a,b   Tsai, Horng Jyh ^b   Kuo, Chih ^b   Chen, Gin Den ^b   Lin, Long Yau ^b,c   Huang, Che Cheng ^a   Luo, Kan Hung ^a  

^a KUANG TIEN GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Immunochemotherapy; Primary non Hodgkin's lymphoma; Rituximab; Uterine body

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CASE REPORT; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; ENDOMETRIUM; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL EXAMINATION; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; UTERINE CERVIX; UTERUS; ABDOMINAL HYSTERECTOMY; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; FOLLOW UP; GENITAL TRACT TUMOR; MENOPAUSE; OUTCOME ASSESSMENT; PRIMARY TUMOR; SALPINGOOOPHORECTOMY; UTERINE CERVIX CANCER; UTERUS CANCER; LARGE CELL LYMPHOMA; PATHOLOGY;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PREDNISOLONE; UTERINE NEOPLASMS; VINCRISTINE;

EID: 52649159277     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2008.00919.x     Document Type: Article

References (20)

1. Szantho A, Balega JJ, Csapo Z, Sreter LL, Matolcsy A, Papp Z. Primary non-Hodgkin's lymphoma of the uterine cervix successfully treated by neoadjuvant chemotherapy: case report. Gynecol Oncol 2003 89 : 171 174.
2. Gabriele A, Gaudiano L. Primary malignant lymphoma of the cervix: a case report. J Reprod Med 2003 48 : 899 901.
3. Katsumata N, Matsuno Y, Nakayama H et al. Prognostic factors and a predictive model of follicular lymphoma: a 25-year study at a single institution in Japan. Jpn J Clin Oncol 1996 26 : 445 454.
4. Heredia F, Bravo M, Pierotic M, Majlis A, Carmona L. Neoadjuvant combined chemotherapy followed by external whole pelvic irradiation in two cases of primary extranodal non-Hodgkin's lymphoma of the uterine cervix. Gynecol Oncol 2005 97 : 285 287.
5. Signorelli M, Maneo A, Cammarota S et al. Conservative management in primary genital lymphomas: the role of chemotherapy. Gynecol Oncol 2007 104 : 416 421.
6. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003 14 : 520 535.
7. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003 22 : 7359 7368.
8. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and Genetics of Haematopoietic and Lymphoid Tissue. World Health Organization Classification of Tumors. Lyon : IARC Press, 2001.
9. Greene FL, Page, DL, Fleming, ID et al. (eds). AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 6th edn. New York : Springer Verlag, 2002.
10. Armitage JO. Staging Non-Hodgkin lymphoma. CA Cancer J Clin 2005 55 : 368 376.
11. Shipp M, Harrington D, Anderson J et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993 329 : 987 994.
12. De Frenza N, Magni M, Trebbi G. Primary lymphoma of the uterus. A case report. Minerva Ginecol 2003 55 : 77 79.
13. Hu Y, Feng FY, Zhang P, Zhou LQ, Zhang WH, Wang QL. Primary non-Hodgkin lymphoma in the female genital system: a report of 28 cases. Zhonghua Zhong Liu Za Zhi 2003 25 : 486 489.
14. Yamane T, Kirimoto K, Fujita M et al. Ovarian involvement as an initial manifestation of malignant lymphoma. Jpn J Clin Oncol 1989 19 : 163 166.
15. Suzuki Y, Tamaki Y, Hasegawa M, Maebayashi K, Mitsuhashi N. Magnetic resonance images of primary malignant lymphoma of the uterine body: a case report. Jpn J Clin Oncol 2000 30 : 519 521.
16. Takács I, Eros N, Bene I et al. Successful treatment of relapse of an intravascular B-cell lymphoma with rituximab-CHOP polychemotherapy. Ann Hematol 2004 83 : 608 610.
17. Dillman RO. Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. Semin Oncol 2003 30 : 434 447.
18. Feuring-Buske M, Kneba M, Unterhalt M et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 2000 79 : 493 500.
19. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005 105 : 1417 1423.
20. Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2006 66 : 791 820.